MiR‐150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1
暂无分享,去创建一个
H. Kuwano | H. Kato | T. Miyazaki | M. Nakajima | T. Yokobori | M. Sakai | A. Sano | M. Sohda | N. Tanaka | T. Inose | Shigemasa Suzuki | Takanori Inose
[1] M. Chen,et al. miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1 , 2012, Clinical & Experimental Metastasis.
[2] Ha Won Kim,et al. microRNA-150 Regulates Mobilization and Migration of Bone Marrow-Derived Mononuclear Cells by Targeting Cxcr4 , 2011, PloS one.
[3] I. Haviv,et al. The social aspects of EMT-MET plasticity , 2011, Nature Medicine.
[4] S. Law,et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor , 2011, Gut.
[5] M. Soares,et al. Identification of Differentially Expressed MicroRNAs in Osteosarcoma , 2011, Sarcoma.
[6] K. Basso,et al. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. , 2011, Blood.
[7] Jiannis Ragoussis,et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization , 2011, Nature Medicine.
[8] H. Tagawa,et al. The role of microRNA-150 as a tumor suppressor in malignant lymphoma , 2011, Leukemia.
[9] Simone Brabletz,et al. The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer? , 2010, EMBO reports.
[10] M. Herlyn,et al. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. , 2010, Cancer research.
[11] Tint Lwin,et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. , 2010, Blood.
[12] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[13] Julia Schüler,et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs , 2009, Nature Cell Biology.
[14] S. Fedele,et al. MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. , 2009, Recent patents on cardiovascular drug discovery.
[15] R. Weinberg,et al. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.
[16] Borja Saez,et al. Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth , 2008, Molecular Cancer Research.
[17] Robert G. Ramsay,et al. MYB function in normal and cancer cells , 2008, Nature Reviews Cancer.
[18] M. Korpal,et al. The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis , 2008, RNA biology.
[19] T. Komori,et al. Snail‐associated epithelial–mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression , 2008, The Journal of pathology.
[20] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[21] S. Kauppinen,et al. LNA-mediated microRNA silencing in non-human primates , 2008, Nature.
[22] D. Sugarbaker,et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Val Gebski,et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. , 2007, The Lancet. Oncology.
[24] G. Hannon,et al. Control of translation and mRNA degradation by miRNAs and siRNAs. , 2006, Genes & development.
[25] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[26] R. Malthaner,et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis , 2004, BMC medicine.
[27] 鈴木 茂正. Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness , 2012 .
[28] George A. Calin,et al. RNA interference in the clinic: challenges and future directions , 2011, Nature Reviews Cancer.
[29] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[30] F. Saggioro,et al. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. , 2009, The Journal of clinical endocrinology and metabolism.
[31] Fang Zhou,et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. , 2008, Cancer research.
[32] Peter D Siersema,et al. Esophageal cancer. , 2008, Gastroenterology clinics of North America.
[33] H. Soifer,et al. MicroRNAs in disease and potential therapeutic applications. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.